Tenofovir alafenamide fumarate for the treatment of HIV infection

R. Sampath, J. Zeuli, S. Rizza, Z. Temesgen

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Tenofovir alafenamide fumarate is a recently developed prodrug of tenofovir, a nucleotide analogue reverse transcriptase inhibitor with potent inhibitory activity against HIV. The utility of a previously developed tenofovir prodrug, tenofovir disoproxil fumarate, had been hampered by renal and bone mineral adverse events. Tenofovir alafenamide fumarate overcomes the shortcomings of tenofovir disoproxil fumarate by delivering high intracellular concentrations of the parent drug, tenofovir, while substantially reducing systemic exposure. Tenofovir alafenamide fumarate is currently available as a component of three fixed-dose products: i) coformulation with emtricitabine; ii) coformulation with elvitegravir, cobicistat and emtricitabine; and iii) coformulation with rilpivirine and emtricitabine.

Original languageEnglish (US)
Pages (from-to)617-625
Number of pages9
JournalDrugs of Today
Issue number11
StatePublished - Nov 2016


  • AIDS
  • Antiretroviral therapy
  • HIV
  • Nucleotide reverse transcriptase inhibitors
  • Tenofovir
  • Tenofovir alafenamide

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Tenofovir alafenamide fumarate for the treatment of HIV infection'. Together they form a unique fingerprint.

Cite this